Skip to main content
. Author manuscript; available in PMC: 2010 Sep 15.
Published in final edited form as: Cancer Res. 2009 Aug 25;69(18):7357–7365. doi: 10.1158/0008-5472.CAN-09-0064

Figure 2. Western blot and Immunohistochemical (IHC) analyses of IRX2 and TBL1XR1.

Figure 2

A) Protein expression, analyzed by Western blot, showed that both IRX2 and TBL1XR1 protein expression increased progressively from MCF10A to MCF10AT to the malignant cells, MCF10CA1h and MCF10CA1a. B) IHC with antibodies against IRX2 on tissue microarray (TMA) slides is shown. Two tumor cores for each negative (IRX2-), weak-positive (IRX2+) and strong-positive (IRX2++) are shown together with numbers and percentage of each staining category among the 85 tumor samples.